Details of the Drug

General Information of Drug (ID: DMXU5LZ)

Drug Name
CRS-207
Indication
Disease Entry ICD 11 Status REF
Gastric adenocarcinoma 2B72 Phase 2 [1]
Mesothelioma 2C51.2 Phase 2 [1]
Pancreatic cancer 2C10 Phase 2 [2]
Ovarian cancer 2C73 Phase 1/2 [1]
Drug Type
Vaccine
Cross-matching ID
UNII
JJX4JHS4PO
DrugBank ID
DB17323
TTD ID
D02WSB
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
3 Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33.